This revised proposal is designed to test the hypothesis that talin and vinculin play a role in attaching GPIIb-IIIa to the platelet cytoskeleton via an interaction with the cytoplasmic domains of this integrin. GPIIb-IIIa is the platelet fibrinogen and vWF receptor. As a consequence of binding to these molecules, GPIIb-IIIa becomes associated with the platelet cytoskeleton, which may contribute to the role of GPIIb-IIIa in clot retraction, tyrosine phosphorylation, receptor clustering and redistribution. The Applicant found that talin, vinculin and actin co-purify with GPIIb-IIIa by RGD affinity chromatography and co-distribute with GPIIb-IIIa in thrombin-stimulated platelets. The Specific Aims of this proposal are 1) To demonstrate direct binding of purified talin or vinculin to activated GPIIb-IIIa. This will be done by measuring simultaneous binding of fibrinogen and talin or vinculin to GPIIb-IIIa in double label experiments. GPIIb-IIIa will be activated by RGD peptide pretreatment of anti-LIBS6. Also, immunoprecipitation studies will be performed to detect interactions of talin and vinculin with GPIIb-IIIa. 2) To localize specific determinants within the cytoplasmic domains of GPIIb-IIIa mediating interactions with cytoskeletal proteins. This will be done with recombinant GPIIb-IIIa truncated or mutated in the cytoplasmic domain. 3) To examine the functional significance of GPIIb-IIIa association with the platelet cytoskeleton by attempting to inhibit this interaction in permeabilized cells with synthetic peptides mimicking the cytoplasmic sequences or with anti-cytoplasmic domain antibodies, and 4) To investigate the possibility that fibrinogen binding to GPIIb-IIIa changes the conformation of the receptor cytoplasmic domains. This will be accomplished with LIBS antibodies that recognize the cytoplasmic domains of GPIIb-IIIa.
NIH ExPorter
NIH ExPorter